Gelonghui September 12 | Hokuriku Pharmaceutical (300016.SZ) was surveyed by a specific target on September 11, 2024. Regarding “the company's expansion in overseas markets,” the company said that after solid groundwork and unremitting exploration in previous years, the results of the company's overseas market expansion efforts were outstanding. In the first half of 2024, the company successfully launched its entire line of contrast products and achieved a significant increase in revenue. In terms of APIs, not only does Haichang Pharmaceutical continue to expand overseas markets for its iodine APIs, but the Cangzhou branch has also gradually internationalized the production of gadolinium APIs. With the completion of EU EDQMGMP certification and Brazilian compliance certification, the internationalization of the company's contrast products is expected to accelerate further. The registration of Jiuwei Zhenxin granules in Hong Kong and Thailand continues to proceed according to plan, creating conditions for export to Southeast Asia and other places.